Pharmaceuticals,
Journal Year:
2023,
Volume and Issue:
16(2), P. 151 - 151
Published: Jan. 19, 2023
Dementia,
most
often
associated
with
neurodegenerative
diseases,
affects
millions
of
people
worldwide,
predominantly
the
elderly.
Unfortunately,
no
treatment
is
still
available.
Therefore,
there
an
urgent
need
to
address
this
situation.
This
review
presents
state
art
drug
discovery
and
developments
in
targeting
dementia.
Several
approaches
are
discussed,
such
as
repurposing,
use
small
molecules,
phosphodiesterase
inhibitors.
Furthermore,
also
provides
insights
into
clinical
trials
these
molecules.
Emphasis
has
been
placed
on
molecules
multi-target-directed
ligands,
well
disease-modifying
therapies.
Finally,
attention
drawn
possibilities
applications
nanotechnology
managing
Current Neuropharmacology,
Journal Year:
2022,
Volume and Issue:
21(3), P. 493 - 516
Published: May 7, 2022
Abstract:
Blood-Brain
Barrier
(BBB)
acts
as
a
highly
impermeable
barrier,
presenting
an
impediment
to
the
crossing
of
most
classical
drugs
targeted
for
neurodegenerative
diseases
including
Parkinson's
disease
(PD).
About
nature
and
other
potential
molecules,
they
impose
unavoidable
doserestricted
limitations
eventually
leading
failure
therapy.
However,
many
advancements
in
formulation
technology
modification
delivery
approaches
have
been
successful
delivering
drug
brain
therapeutic
window.
The
nose
(N2B)
employing
nanoformulation,
is
one
such
emerging
approach,
overcoming
both
delivery-associated
limitations.
This
latter
approach
offers
increased
bioavailability,
greater
patient
acceptance,
lesser
metabolic
degradation
drugs,
circumvention
BBB,
ample
loading
along
with
controlled
release
drugs.
In
N2B
delivery,
intranasal
(IN)
route
carries
therapeutics
firstly
into
nasal
cavity
followed
by
through
olfactory
trigeminal
nerve
connections
linked
mucosa.
being
explored
biologicals
like
neuropeptides
mitochondria.
Meanwhile,
this
system
associated
critical
challenges
consisting
mucociliary
clearance,
enzymes,
translocations
efflux
mechanisms.
These
finally
culminated
development
suitable
surfacemodified
nano-carriers
Focused-
Ultrasound-Assisted
IN
FUS-IN
technique
which
has
expanded
horizons
delivery.
Hence,
nanotechnology,
collaboration
advances
administration,
diversified
treating
PD.
present
review
discusses
physiology
limitation
current
nanocarrier
technical
assisting
Biotechnology Advances,
Journal Year:
2022,
Volume and Issue:
57, P. 107948 - 107948
Published: March 23, 2022
The
spread
of
antimicrobial
resistance
in
Gram-positive
pathogens
represents
a
threat
to
human
health.
To
counteract
the
current
lack
novel
antibiotics,
alternative
antibacterial
treatments
have
been
increasingly
investigated.
This
review
covers
last
decade's
developments
using
nanoparticles
as
carriers
for
two
classes
frontline
antibiotics
active
on
multidrug-resistant
pathogens,
i.e.,
glycopeptide
and
daptomycin.
Most
reviewed
papers
deal
with
vancomycin
nanoformulations,
being
teicoplanin-
daptomycin-carrying
nanosystems
much
less
Special
attention
is
addressed
nanoantibiotics
used
contrasting
biofilm-associated
infections.
status
art
related
nanoantibiotic
toxicity
critically
reviewed.
Molecules,
Journal Year:
2022,
Volume and Issue:
27(15), P. 4839 - 4839
Published: July 28, 2022
Alzheimer's
disease
(AD)
is
a
chronic
dysfunction
of
neurons
in
the
brain
leading
to
dementia.
It
characterized
by
gradual
mental
failure,
abnormal
cognitive
functioning,
personality
changes,
diminished
verbal
fluency,
and
speech
impairment.
caused
neuronal
injury
cerebral
cortex
hippocampal
area
brain.
The
number
individuals
with
AD
growing
at
quick
rate.
pathology
behind
progress
intraneuronal
fibrillary
tangles,
accumulation
amyloid
plaque,
loss
cholinergic
neurons,
decrease
choline
acetyltransferase.
Unfortunately,
cannot
be
cured,
but
its
progression
can
delayed.
Various
FDA-approved
inhibitors
cholinesterase
enzyme
such
as
rivastigmine,
galantamine,
donepezil,
NDMA
receptor
(memantine),
are
available
manage
symptoms
AD.
An
exhaustive
literature
survey
was
carried
out
using
SciFinder's
reports
from
Association,
PubMed,
Clinical
Trials.org.
explored
thoroughly
obtain
information
on
various
strategies
prevent
In
context
present
scenario,
several
being
tried
including
clinical
trials
for
treatment
We
have
discussed
pathophysiology,
targets,
drugs,
drugs
against
goal
this
study
shed
light
current
developments
options,
utilizing
phytopharmaceuticals,
nanomedicines,
nutraceuticals,
gene
therapy.
Pharmaceuticals,
Journal Year:
2023,
Volume and Issue:
16(2), P. 151 - 151
Published: Jan. 19, 2023
Dementia,
most
often
associated
with
neurodegenerative
diseases,
affects
millions
of
people
worldwide,
predominantly
the
elderly.
Unfortunately,
no
treatment
is
still
available.
Therefore,
there
an
urgent
need
to
address
this
situation.
This
review
presents
state
art
drug
discovery
and
developments
in
targeting
dementia.
Several
approaches
are
discussed,
such
as
repurposing,
use
small
molecules,
phosphodiesterase
inhibitors.
Furthermore,
also
provides
insights
into
clinical
trials
these
molecules.
Emphasis
has
been
placed
on
molecules
multi-target-directed
ligands,
well
disease-modifying
therapies.
Finally,
attention
drawn
possibilities
applications
nanotechnology
managing
